Maze Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and thank you for joining Guggenheim's 3rd Annual Healthcare Innovation Conference. I'm Debjit, one of the therapeutic analysts at Guggenheim, and it's my pleasure to welcome Jason Coloma, the CEO of Maze Therapeutics, as our next presenting company. Thank you so much, Jason, for making time for us.
Yeah, thanks for having us.
Well, you just put up the quarterly update yesterday.
Maybe we can pick it up from there because the study is fully enrolled and maybe over-enrolled. From what we understand, you have a better handle of baselines right now versus last year. Maybe walk us through what kind of patients we'll get to see in 2027.
Yeah, I think it's, for people that are out there that are not familiar with us, we use genetics as our handle to develop small molecule programs for programs like APOL1 kidney disease and for diseases like that. We had our earnings announcement yesterday, and I think a really positive trend in what we saw in enrollment. We had talked about this, that there were a few factors that would be helpful in kind of thinking about enrollment from the administrative analysis that we had published earlier in the year. One is, I think there's just more disease awareness from a lot of the efforts that are happening, not just from the companies that are sponsors in the trials, but also more importantly, the overall community, the nephrology community, the patient advocacy groups.
So, I think there's just a larger awareness around the disease and the importance of testing to at least know the information that might direct you, right now, no approved therapies for APOL1 kidney disease, but at the same time, it might help them direct them to a study and at least have clarity about why they might be suffering from the disease that they have. So, I think that was incredibly helpful. I think the other thing is just in the sense of what we've been able to accomplish operationally, which was to be able to adjust. That's why we did some of the administrative analysis at that interim to really adjust what we were doing operationally, what sites were going to be the most productive, how do we engage better with the community. So, some of the adjustments we've been doing there have obviously been helpful.
I think the third thing, which was incredibly helpful, is we had data. Part of the idea that we took the administrative analysis, it really does help engage the nephrologists as well as the patients on why they might want to consider participating in a study. I think all three of those things really helped us in the sense of being able to think about enrollment. We had talked about and guided previously that we would have, across three different cohorts, 10-15 patients. So, that's 30-45. We've actually exceeded that. Over 50 patients enrolled into the study, and I think that just speaks to a lot of the hard work that our team was able to do over the last few months.
I think when you think about that, Debjit, in the sense of what that means, in terms of the context, other sponsor studies that were also in phase II had around 50 patients. So, I think it was important to have a size of a study that was comparable to those in front of us or aside us in terms of APOL1 kidney disease. I think for our team, it also gives us the confidence that we can enroll this study, the next study, right? In terms of the pivotal, because of some of the things that we can carry forward in terms of tactics and strategies about how to enroll the study. I think that was a question mark for many investors, and I think we were able to make these adjustments.
I think the other thing that we had talked about is we have a second program, SLC6A19 inhibitor called MZE782. Earlier in the year, we had guided that we would be able to start that study by the middle of the year. We did that on time, as we had promised our investors. That's going very well, as we've gotten that study launched. It could be best in class in PKU, which is, we're seeing a lot of resurgence of interest in PKU as a disease. In particular, other launches that have been very successful in the market have really painted a picture of really sort of the unmet need that patients have. We're excited about being able to enroll that study and being able to have that data in 2027.
The last thing is we're also using SLC inhibition in the context of chronic kidney disease, and what we described in our earnings was the ability to start that study in 2027. A lot of things going great for the company in the sense of those studies. I think we also highlighted a few things that we've been able to do operationally, and then our balance sheet's strong. That gets us through all of the different data catalysts that we will be upcoming, including APOL1, SLC, PKU, and SLC CKD. A lot of good things going on at the company.
Well, a lot to unpack there. Let's start with MZE829. Just refresh us on the differentiated mechanism of action for MZE829 versus inaxaplin.
Yeah. I think for those that are not as familiar with APOL1 inhibitors, the concept is that under certain conditions, patients have this overexpression of APOL1s that really embed themselves in kidney cells or podocytes, causing eventually this nephrotoxicity. So, at minimum, what you want to be able to do, because they become these ungated pores, if you will, in the kidney cells, is you want to block the pore from sort of allowing for certain things to coming into the cell. The other thing that you may want to do is not only just block the pores, but also disrupt the assembly of those pores from ever happening. What was interesting is we started to generate our molecule, which was informed by not just genetics, but other things that we were able to do pre-clinically.
We knew that we were binding to the pore, which was at a different location than compounds that have been described in the literature. They're both pore inhibitors, but they bind to a different site. We think that confers a different particular mechanism. The other thing that we saw is that we were incredibly more potent, at least in a preclinical model, looking at proteinuria as the readout. To try to help understand that, we were trying to look at systematically what mechanism we might be able to do in terms of a pore inhibitor. It turns out our compound, MZE829, not only blocks the pore, but it disrupts the assembly of the pore from ever forming, which is different than what's been described in the literature to date of any other compound, which seem to only be able to block the pore. Why is that important? It's because APOL1 itself, it rapidly forms and reforms in the kidney.
There's some description in the literature that it reforms every 42 minutes or every hour. It doesn't really matter to us that you're blocking the pore. If they keep forming and keep embedding themselves in the podocyte, you might be still have the cell damage ultimately causing the issue. The fact that we have this differentiated mechanism gives us at least a reason to believe we could have some improved efficacy. We saw that at least in the preclinical data and hints of that in our early administrative analysis.
Yeah. Let's talk about the data from earlier this year. If you were just to focus on the FSGS patients.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
